Results 171 to 180 of about 648,597 (288)
ABSTRACT Pathogenic variants in KIF1C cause Spastic Paraplegia 58 (SPG58), typically presenting with cerebellar ataxia and spastic paraparesis. We report two unrelated patients with spastic paraparesis, cerebellar ataxia, and tremor. Whole‐exome sequence analysis identified novel homozygous variants in the motor domain of KIF1C (NM_006612.6): c.921G>A (
Akihiko Mitsutake +12 more
wiley +1 more source
Building a healthcare data warehouse: considerations, opportunities, and challenges. [PDF]
Knezevic Ivanovski T +4 more
europepmc +1 more source
A metadata schema for data objects in clinical research [PDF]
Steve Canham, Christian Ohmann
openalex +1 more source
Developmental, Neuroanatomical and Cellular Expression of Genes Causing Dystonia
ABSTRACT Objective Dystonia is one of the most common movement disorders, with variants in multiple genes identified as causative. However, an understanding of which developmental stages, brain regions, and cell types are most relevant is crucial for developing relevant disease models and therapeutics.
Darren Cameron +5 more
wiley +1 more source
The mediating role of cognitive schemas in the relationship between parenting styles and suicidal ideation in adolescents: a structural equation modeling approach. [PDF]
Hosseini FA +4 more
europepmc +1 more source
Objective A leading cause of death among patients with scleroderma (SSc), interstitial lung disease (ILD) remains challenging to prognosticate. The discovery of biomarkers that accurately determine which patients would benefit from close monitoring and aggressive therapy would be an essential clinical tool.
Cristina M. Padilla +13 more
wiley +1 more source
Association of Shock Index and Variants with Mortality in Acute Pulmonary Embolism. [PDF]
Upchurch CP +4 more
europepmc +1 more source
Reducing Uncertainty of Schema Matching via Crowdsourcing with Accuracy Rates [PDF]
Chen Zhang +4 more
openalex +1 more source
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti +19 more
wiley +1 more source

